BEAM
Price
$29.01
Change
+$2.16 (+8.04%)
Updated
Dec 20 closing price
72 days until earnings call
RXRX
Price
$6.04
Change
-$0.05 (-0.82%)
Updated
Dec 20, 04:59 PM (EDT)
72 days until earnings call
Ad is loading...

BEAM vs RXRX

Header iconBEAM vs RXRX Comparison
Open Charts BEAM vs RXRXBanner chart's image
Beam Therapeutics
Price$29.01
Change+$2.16 (+8.04%)
Volume$2.74M
CapitalizationN/A
Recursion Pharmaceuticals
Price$6.04
Change-$0.05 (-0.82%)
Volume$233.5K
CapitalizationN/A
BEAM vs RXRX Comparison Chart
Loading...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BEAM vs. RXRX commentary
Dec 22, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a Hold and RXRX is a Hold.

COMPARISON
Comparison
Dec 22, 2024
Stock price -- (BEAM: $29.01 vs. RXRX: $6.03)
Brand notoriety: BEAM and RXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 220% vs. RXRX: 186%
Market capitalization -- BEAM: $2.4B vs. RXRX: $2.36B
BEAM [@Biotechnology] is valued at $2.4B. RXRX’s [@Biotechnology] market capitalization is $2.36B. The market cap for tickers in the [@Biotechnology] industry ranges from $464.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 0 FA rating(s) are green whileRXRX’s FA Score has 0 green FA rating(s).

  • BEAM’s FA Score: 0 green, 5 red.
  • RXRX’s FA Score: 0 green, 5 red.
According to our system of comparison, BEAM is a better buy in the long-term than RXRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 3 TA indicator(s) are bullish while RXRX’s TA Score has 5 bullish TA indicator(s).

  • BEAM’s TA Score: 3 bullish, 4 bearish.
  • RXRX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, RXRX is a better buy in the short-term than BEAM.

Price Growth

BEAM (@Biotechnology) experienced а +3.87% price change this week, while RXRX (@Biotechnology) price change was -13.24% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.20%. For the same industry, the average monthly price growth was -1.27%, and the average quarterly price growth was +2.17%.

Reported Earning Dates

BEAM is expected to report earnings on Mar 04, 2025.

RXRX is expected to report earnings on Mar 04, 2025.

Industries' Descriptions

@Biotechnology (-2.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($2.41B) and RXRX($2.36B) have the same market capitalization . BEAM YTD gains are higher at: 6.576 vs. RXRX (-38.844). BEAM has higher annual earnings (EBITDA): -160.83M vs. RXRX (-350.86M). BEAM has more cash in the bank: 926M vs. RXRX (428M). RXRX has less debt than BEAM: RXRX (90.6M) vs BEAM (162M). BEAM has higher revenues than RXRX: BEAM (350M) vs RXRX (64.6M).
BEAMRXRXBEAM / RXRX
Capitalization2.41B2.36B102%
EBITDA-160.83M-350.86M46%
Gain YTD6.576-38.844-17%
P/E RatioN/AN/A-
Revenue350M64.6M542%
Total Cash926M428M216%
Total Debt162M90.6M179%
TECHNICAL ANALYSIS
Technical Analysis
BEAMRXRX
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
68%
Momentum
ODDS (%)
Bullish Trend 3 days ago
83%
Bearish Trend 3 days ago
88%
MACD
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
83%
Bearish Trend 3 days ago
88%
Advances
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 14 days ago
83%
Declines
ODDS (%)
Bearish Trend 5 days ago
85%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
80%
Bullish Trend 3 days ago
86%
Aroon
ODDS (%)
N/A
Bullish Trend 5 days ago
81%
View a ticker or compare two or three
Ad is loading...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JDURX14.920.22
+1.50%
PGIM Jennison Utility R
MEIIX48.760.46
+0.95%
MFS Value I
ABMIX21.960.20
+0.92%
AMG River Road Mid Cap Value I
FOBPX19.700.15
+0.77%
Tributary Balanced Instl Plus
RTRRX8.050.05
+0.63%
Royce Small-Cap Total Return R

RXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RXRX has been loosely correlated with CRSP. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if RXRX jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RXRX
1D Price
Change %
RXRX100%
-0.99%
CRSP - RXRX
62%
Loosely correlated
+0.83%
BEAM - RXRX
61%
Loosely correlated
+8.04%
PRME - RXRX
56%
Loosely correlated
+3.94%
NTLA - RXRX
54%
Loosely correlated
+0.83%
EXAI - RXRX
52%
Loosely correlated
N/A
More